It was demonstrated that cisplatin‐induced METTL3‐mediated m6A modification increased the mRNA stability of SREBP1c, thereby upregulating its expression, while depletion of SREBP1c markedly ameliorated cisplatin‐induced AKI and its progression to CKD. Here, METTL3 is linked to chronic kidney disease.